HOW I DO IT

• How I Do It: Optilume BPH catheter system

  Elterman S. Dean, Gao Bruce, Zorn C. Kevin, Bhojani Naeem, Te Alexis, Chughtai Bilal, Kaplan A. Steven Division of Urology, Department of Surgery, University of Toronto, Ontario, Canada

  ---

  Benign prostatic hyperplasia (BPH) is a common and progressive disease affecting aging men which has a significant impact on quality of life. The Optilume BPH Catheter System (Optilume BPH) is a prostatic dilation system that combines balloon dilation with a localized transfer of paclitaxel to maintain long term patency. Optilume BPH can be deployed using standard rigid cystoscopy without general anesthesia in an office setting. Prospective data indicate that Optilume BPH has favorable functional and sexual patient outcomes. Readers will familiarize themselves with Optilume BPH, significant historical studies and the technique for deploying Optilume BPH.

  Keywords: prostate, BPH, MIST, Optilume,

  Jun 2023 (Vol. 30, Issue 3 , Page 11568)
  PDF (396.1KB)Free
• How I Do It: Penthrox in Urology

  Ferreira Roseanne, Zorn C. Kevin, Bhojani Naeem, Chughtai Bilal, Elterman S. Dean Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada

  ---

  Penthrox is a portable handheld inhaler that delivers a low dose of methoxyflurane - an anesthetic with analgesic effects, rapid onset of action, and a favorable side-effect profile. It has been widely used for acute pain management in Australia for the past 40 years. Currently, it is approved for use in over 55 countries, including Canada. Prospective randomized studies highlight Penthrox analgesic effectiveness and safety profile for emergency, prehospital and outpatient settings. In addition, the use of multimodal analgesia, specifically Penthrox, can play an important role in the analgesic management of urological procedures, such as prostatic biopsies and office-based minimally invasive surgical therapies. Herein readers will familiarize themselves with Penthrox, significant studies, and technique used for outpatient urological procedures.

  Keywords: urology, analgesia, Penthrox, methoxyflurane, MIST,

  Feb 2023 (Vol. 30, Issue 1 , Page 11448)
  PDF (102.7KB)Free
• How I Do It: Temporarily Implanted Nitinol Device (iTind)

  Elterman Dean, Gao Bruce, Zorn C. Kevin, Bhojani Naeem, Chughtai Bilal, MD Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada

  ---

  Benign prostatic hyperplasia is a common and progressive disease affecting aging men which has a significant impact on quality of life. The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporary prostatic urethral device which can be deployed using standard flexible cystoscopy without sedation or general anesthesia. The device is left in-situ for 5 to 7 days and is then entirely removed in the office, using an open-ended silicone catheter. Prospective, randomized data indicate that iTind has favorable functional and sexual patient outcomes. Readers will familiarize themselves with iTind, significant historical studies and the technique for deploying iTind using a flexible cystoscope in the office setting.

  Keywords: prostate, BPH, TMIST, iTind,

  Aug 2021 (Vol. 28, Issue 4 , Page 10788)
  PDF (864.7KB)Free